Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16448954 | 1.00 | GPR119 (0.47) | GPR119CYP2C9USP30IKBKBNAMPT | |
| SCHEMBL10135749 | 1.00 | GPR119 (0.47) | GPR119CYP2C9USP30IKBKBNAMPT | |
| SCHEMBL10135780 | 0.93 | GPR119 (0.46) | GPR119CYP2C9NAMPT | |
| SCHEMBL10135625 | 0.87 | GPR119 (0.50) | GPR119CYP2C9NAMPT | |
| SCHEMBL10135796 | 0.86 | GPR119 (0.49) | GPR119CYP2C9NAMPT | |
| SCHEMBL10135645 | 0.86 | GPR119 (0.47) | GPR119NAMPTP2RX7 | |
| SCHEMBL10135623 | 0.85 | GPR119 (0.47) | GPR119CYP2C9NAMPT | |
| SCHEMBL10135673 | 0.85 | GPR119 (0.47) | GPR119CYP2C9NAMPT | |
| SCHEMBL10135633 | 0.85 | GPR119 (0.47) | GPR119CYP2C9NAMPT | |
| SCHEMBL10135696 | 0.84 | GPR119 (0.46) | GPR119CYP2C9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | GPR119 2496/4885CYP2C9 1512/4885USP30 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.